Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ConvaTec ( (GB:CTEC) ) just unveiled an announcement.
Convatec Group Plc announced its total voting rights, revealing that the company’s issued share capital consists of 2,049,789,559 ordinary shares, with 1,242,173 held in treasury. This results in 2,048,547,386 total voting rights, which shareholders can use to determine their interests under the FCA’s rules. Additionally, 4,897,055 shares are in the settlement process following a recent buyback program. This update could impact shareholder decisions and reflects Convatec’s ongoing financial strategies.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Neutral.
ConvaTec’s strong financial performance and strategic positioning are tempered by bearish technical indicators and a high valuation. Regulatory challenges may pose risks, but the company’s innovation pipeline and operational strength support a moderately positive outlook.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
Convatec is a global medical products and technologies company that focuses on solutions for managing chronic conditions. It holds leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 employees, Convatec operates in around 90 countries, aiming to improve patient outcomes and reduce care costs. The company is part of the FTSE 100 Index and reported revenues exceeding $2 billion in 2024.
Average Trading Volume: 7,971,845
Technical Sentiment Signal: Hold
Current Market Cap: £4.82B
For a thorough assessment of CTEC stock, go to TipRanks’ Stock Analysis page.